Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma

被引：0
|
作者：
Mi Na Kim
Seung Min Lee
Jin Sung Kim
Seong Gyu Hwang
机构：
[1] CHA University School of Medicine,Division of Gastroenterology, Department of Internal Medicine, CHA Bundang Medical Center
[2] CHA University,Institute for Clinical Research, CHA Bundang Medical Center
[3] School of Medicine,undefined
[4] CMG Pharmaceutical CO.,undefined
[5] LTD,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; Sorafenib; Dual PI3K/mTOR inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：809 / 817
页数：8
相关论文
共 50 条
  • [41] Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
    Chi Hang Wong
    Herbert H. Loong
    Connie W. C. Hui
    Cecilia P. Y. Lau
    Edwin P. Hui
    Brigette B. Y. Ma
    Anthony T. C. Chan
    Investigational New Drugs, 2013, 31 : 1399 - 1408
  • [42] Preclinical efficacy of the novel dual PI3K/mTOR inhibitor, BEZ235 compared with RAD001 in HER2+breast tumors
    De, Pradip K. R.
    Sun, Yuliang
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2011, 71
  • [43] Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
    Wong, Chi Hang
    Loong, Herbert H.
    Hui, Connie W. C.
    Lau, Cecilia P. Y.
    Hui, Edwin P.
    Ma, Brigette B. Y.
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1399 - 1408
  • [44] Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells
    Yu, Hao
    Shi, Ni
    Pan, Zui
    Chen, Tong
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Combination of PI3K/mTOR Inhibition Demonstrates Efficacy in Human Chordoma
    Schwab, Joseph
    Antonescu, Cristina
    Boland, Patrick
    Healey, John
    Rosenberg, Andrew
    Nielsen, Petur
    Iafrate, John
    Delaney, Thomas
    Yoon, Sam
    Choy, Edwin
    Harmon, David
    Raskin, Kevin
    Yang, Cao
    Mankin, Henry
    Springfield, Dempsey
    Hornicek, Francis
    Duan, Zhenfeng
    ANTICANCER RESEARCH, 2009, 29 (06) : 1867 - 1871
  • [46] ANTI-ANGIOGENIC EFFICACY OF BEVACIZUMAB ALONE AND IN COMBINATION WITH A DUAL PI3K/mTOR INHIBITOR IN AN ORTHOTOPIC MODEL OF MALIGNANT GLIOMA: A MULTIMODAL NEURO-IMAGING APPROACH
    O'Halloran, Philip
    Viel, Thomas
    Schwegmann, Katrin
    Wachsmuth, Lydia
    Wagner, Stefan
    Kopka, Klaus
    Dicker, Patrick
    Faber, Cornelius
    Jarzabek, Monika
    Hermann, Sven
    Schafers, Michael
    O'Brien, David
    Prehn, Jochen
    Jacobs, Andreas
    Byrne, Annette
    NEURO-ONCOLOGY, 2013, 15 : 8 - 8
  • [47] Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer
    Chang, Lei
    Graham, Peter H.
    Hao, Jingli
    Jie Ni
    Bucci, Joseph
    Cozzi, Paul J.
    Kearsley, John H.
    Li, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S50 - S50
  • [48] PRECLINICAL STUDIES OF THE PI3K/MTOR DUAL INHIBITOR, PF-04691502, IN BREAST CANCER CELL LINES
    Kan, J.
    Yuan, J.
    Lee, N.
    Pavlicek, A.
    Ching, K.
    Cao, J.
    Garza, S.
    Hook, K.
    Christensen, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 55 - 55
  • [49] Preclinical PKPD modeling and human dose projection of PF-046915027, a PI3K/mTOR dual inhibitor
    Luu, Kenneth T.
    Zhang, Eric
    Bagrodia, Shubha
    Yuan, Jing
    CANCER RESEARCH, 2010, 70
  • [50] COMBINATION OF HDAC INHIBITOR AND PI3K/MTOR INHIBITOR SYNERGISTICALLY INDUCES APOPTOSIS IN DIPG
    Barnett, Katie
    Kwon, HyukJean
    Raabe, Eric
    Eberhart, Charles
    NEURO-ONCOLOGY, 2022, 24 : 212 - 213
12345